JP2023552998A5 - - Google Patents
Info
- Publication number
- JP2023552998A5 JP2023552998A5 JP2023533999A JP2023533999A JP2023552998A5 JP 2023552998 A5 JP2023552998 A5 JP 2023552998A5 JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023552998 A5 JP2023552998 A5 JP 2023552998A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cells
- immune cells
- edited
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121206P | 2020-12-03 | 2020-12-03 | |
| US63/121,206 | 2020-12-03 | ||
| US202163201159P | 2021-04-15 | 2021-04-15 | |
| US63/201,159 | 2021-04-15 | ||
| US202163236167P | 2021-08-23 | 2021-08-23 | |
| US63/236,167 | 2021-08-23 | ||
| US202163264234P | 2021-11-17 | 2021-11-17 | |
| US202163264223P | 2021-11-17 | 2021-11-17 | |
| US63/264,223 | 2021-11-17 | ||
| US63/264,234 | 2021-11-17 | ||
| PCT/US2021/072715 WO2022120370A2 (en) | 2020-12-03 | 2021-12-02 | Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552998A JP2023552998A (ja) | 2023-12-20 |
| JP2023552998A5 true JP2023552998A5 (enExample) | 2024-12-10 |
Family
ID=81854915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533999A Pending JP2023552998A (ja) | 2020-12-03 | 2021-12-02 | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240335536A1 (enExample) |
| EP (1) | EP4255453A4 (enExample) |
| JP (1) | JP2023552998A (enExample) |
| AU (1) | AU2021392809A1 (enExample) |
| CA (1) | CA3200367A1 (enExample) |
| WO (1) | WO2022120370A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| AU2021286655A1 (en) * | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| CN117384853B (zh) * | 2022-07-11 | 2025-12-19 | 士泽生物医药（苏州）有限公司 | 一种表达pvr的通用型细胞及其制备方法 |
| CN117384852B (zh) * | 2022-07-11 | 2026-01-16 | 士泽生物医药（苏州）有限公司 | 一种表达lgals9的通用型细胞及其制备方法 |
| KR20250046298A (ko) * | 2022-08-03 | 2025-04-02 | 엔카르타, 인크. | 자연 살해 세포 기능을 향상시키기 위한 표적 유전자의 유전자 편집 |
| CN120092090A (zh) * | 2022-11-07 | 2025-06-03 | 上海先博生物科技有限公司 | 工程化嵌合抗原受体免疫细胞及其应用 |
| JP2025538424A (ja) * | 2022-11-16 | 2025-11-28 | ンカルタ・インコーポレイテッド | 併用療法の投与レジメン |
| CN115948341B (zh) * | 2022-11-28 | 2025-05-16 | 上海恩凯细胞技术有限公司 | 敲低nkg2a基因的car-免疫细胞及其用途 |
| EP4687965A1 (en) * | 2023-04-07 | 2026-02-11 | Nkarta, Inc. | Methods for treatment of autoimmune diseases |
| WO2025073908A1 (en) * | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| WO2026041793A1 (en) * | 2024-08-23 | 2026-02-26 | BioNTech SE | Chimeric proteins comprising non-human protein domains for enhancing antigenicity |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6681837B2 (ja) * | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| US10648020B2 (en) * | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法 |
| EP3423580A1 (en) * | 2016-03-04 | 2019-01-09 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| JP2020503043A (ja) * | 2016-12-30 | 2020-01-30 | セルラリティ インコーポレイテッド | 遺伝子改変されたナチュラルキラー細胞 |
| EP3612210A4 (en) * | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| EP3707258A1 (en) * | 2017-11-06 | 2020-09-16 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy |
| CN112041433A (zh) * | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| KR20210005240A (ko) * | 2018-05-03 | 2021-01-13 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포 |
| MX2021006208A (es) * | 2018-11-28 | 2021-10-01 | Univ Texas | Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor. |
| EP3911735A4 (en) * | 2019-01-16 | 2023-07-12 | Beam Therapeutics, Inc. | MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION |
| PE20211959A1 (es) * | 2019-02-15 | 2021-09-30 | Editas Medicine Inc | Celulas asesinas naturales (nk) modificadas para inmunoterapia |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
| AU2021286655A1 (en) * | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
-
2021
- 2021-12-02 EP EP21901656.5A patent/EP4255453A4/en active Pending
- 2021-12-02 CA CA3200367A patent/CA3200367A1/en active Pending
- 2021-12-02 US US18/255,222 patent/US20240335536A1/en active Pending
- 2021-12-02 AU AU2021392809A patent/AU2021392809A1/en active Pending
- 2021-12-02 JP JP2023533999A patent/JP2023552998A/ja active Pending
- 2021-12-02 WO PCT/US2021/072715 patent/WO2022120370A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552998A5 (enExample) | ||
| US11001621B1 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| US20240075143A1 (en) | Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof | |
| JP6285553B2 (ja) | 抗ｃｄ３０キメラ抗原受容体およびその使用 | |
| US10561686B2 (en) | Modified cell expansion and uses thereof | |
| US11566223B2 (en) | Chimeric antigen receptor cell preparation and uses thereof | |
| US20230210905A1 (en) | T cell-antigen coupler with various construct optimizations | |
| US11198737B2 (en) | T cell-antigen coupler with Y177 mutation and methods of uses thereof | |
| WO2017059796A1 (en) | Activation and expansion of t cells | |
| KR20230066007A (ko) | 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도 | |
| JP2025513626A (ja) | Ｃｉｉｔａ遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023035947A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023083003A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023071811A1 (zh) | 工程化免疫细胞及其用途 | |
| CN111607596A (zh) | 修饰的pd-1及其在细胞治疗中的用途 | |
| HK1234091A1 (en) | Trifunctional t cell-antigen coupler and methods and uses thereof |